RWM
KIN

Ritholtz Wealth Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Ritholtz Wealth Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,990
Closed -$55K – 575
2021
Q1 		$55K Buy
+10,990
New +$53.1K ﹤0.01% 445

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Ritholtz Wealth Management's KIN Position: Q2 2021 in Review

Ritholtz Wealth Management sold out of Kindred Biosciences, Inc. (KIN) in Q2 2021, closing a stake of 10,990 shares — an estimated $55K sold.

Ritholtz Wealth Management first reported a position in KIN in Q1 2021 and held it in 1 quarter. The position peaked at $55K in Q1 2021. 87 funds tracked by Wall St. Rank hold KIN as of Q2 2021.

  • Ritholtz Wealth Management reported no remaining Kindred Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Ritholtz Wealth Management sold 10,990 Kindred Biosciences, Inc. shares in Q2 2021, an estimated $55K.
  • Ritholtz Wealth Management first reported a position in Kindred Biosciences, Inc. in Q1 2021 and held it in 1 quarter.
  • Ritholtz Wealth Management's Kindred Biosciences, Inc. position peaked at $55K in Q1 2021.
  • 87 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2021.

Based on Ritholtz Wealth Management's 13F filing for Q2 2021, filed 20 Jul 2021.